| scholarly article | Q13442814 |
| P50 | author | Naiara Beraza | Q50541973 |
| Christian Liedtke | Q53486596 | ||
| P2093 | author name string | Christian Trautwein | |
| Darjus F Tschaharganeh | |||
| Hermann E Wasmuth | |||
| Daniela C Kroy | |||
| Leif E Sander | |||
| Konrad L Streetz | |||
| Arne Giebeler | |||
| Stephanie Erschfeld | |||
| P2860 | cites work | Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway | Q24531184 |
| Central role of suppressors of cytokine signaling proteins in hepatic steatosis, insulin resistance, and the metabolic syndrome in the mouse | Q24564225 | ||
| A central role for JNK in obesity and insulin resistance | Q29619778 | ||
| Strain-specific differences in mouse hepatic wound healing are mediated by divergent T helper cytokine responses | Q36591648 | ||
| Beyond insulin resistance: Innate immunity in nonalcoholic steatohepatitis | Q36669223 | ||
| Neuropoietin attenuates adipogenesis and induces insulin resistance in adipocytes | Q36825535 | ||
| NASH and the risk of cirrhosis and hepatocellular carcinoma in type 2 diabetes | Q36839912 | ||
| Identification of a new JNK inhibitor targeting the JNK-JIP interaction site | Q36938538 | ||
| Differential effects of JNK1 and JNK2 inhibition on murine steatohepatitis and insulin resistance | Q37038490 | ||
| Cytokines in the pathogenesis of fatty liver and disease progression to steatohepatitis: implications for treatment | Q37051418 | ||
| Liver diseases and metabolic syndrome | Q37224466 | ||
| Non-alcoholic fatty liver disease: an overview of prevalence, diagnosis, pathogenesis and treatment considerations | Q37228756 | ||
| Diverse regulation of NF-kappaB and peroxisome proliferator-activated receptors in murine nonalcoholic fatty liver. | Q38336686 | ||
| A stress signaling pathway in adipose tissue regulates hepatic insulin resistance | Q41811449 | ||
| A modified choline-deficient, ethionine-supplemented diet protocol effectively induces oval cells in mouse liver | Q43722483 | ||
| Role of STAT-3 in regulation of hepatic gluconeogenic genes and carbohydrate metabolism in vivo | Q44723555 | ||
| Hepatic microvascular dysfunction during evolution of dietary steatohepatitis in mice | Q45059652 | ||
| Overexpression of Il6 leads to hyperinsulinaemia, liver inflammation and reduced body weight in mice. | Q45877031 | ||
| Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis | Q46524814 | ||
| Lack of gp130 expression in hepatocytes promotes liver injury1 1K.L.S. and T.W. contributed equally to this work | Q57339931 | ||
| Lack of gp130 expression results in more bacterial infection and higher mortality during chronic cholestasis in mice | Q58619570 | ||
| Signal transducer and activator of transcription 3 signaling within hepatocytes attenuates systemic inflammatory response and lethality in septic mice | Q80809740 | ||
| Gene expression patterns in hepatic tissue and visceral adipose tissue of patients with non-alcoholic fatty liver disease | Q81480459 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | steatosis | Q1365091 |
| P304 | page(s) | 463-473 | |
| P577 | publication date | 2010-02-01 | |
| P1433 | published in | Hepatology | Q15724398 |
| P1476 | title | Lack of interleukin-6/glycoprotein 130/signal transducers and activators of transcription-3 signaling in hepatocytes predisposes to liver steatosis and injury in mice | |
| P478 | volume | 51 |
| Q42824021 | A protective role for CD154 in hepatic steatosis in mice |
| Q35573353 | Activation of the GP130-STAT3 axis and its potential implications in nonalcoholic fatty liver disease |
| Q83412055 | Blockade of IL-6 signaling exacerbates liver injury and suppresses antiapoptotic gene expression in methionine choline-deficient diet-fed db/db mice |
| Q36363234 | Both MAPK and STAT3 signal transduction pathways are necessary for IL-6-dependent hepatic stellate cells activation |
| Q27336446 | Chronic IL-6 Administration Desensitizes IL-6 Response in Liver, Causes Hyperleptinemia and Aggravates Steatosis in Diet-Induced-Obese Mice |
| Q35802874 | Chronic administration of recombinant IL-6 upregulates lipogenic enzyme expression and aggravates high-fat-diet-induced steatosis in IL-6-deficient mice |
| Q35867085 | Cytokines and STATs in Liver Fibrosis |
| Q27300594 | Differential role of gp130-dependent STAT and Ras signalling for haematopoiesis following bone-marrow transplantation |
| Q50959095 | Early inflammation-associated factors blunt sterol regulatory element-binding proteins-1-mediated lipogenesis in high-fat diet-fed APPSWE /PSEN1dE9 mouse model of Alzheimer's disease. |
| Q37363773 | Experimental liver fibrosis research: update on animal models, legal issues and translational aspects |
| Q54610301 | Gas6 deficiency prevents liver inflammation, steatohepatitis, and fibrosis in mice. |
| Q36049875 | Hepatic Src homology phosphatase 2 regulates energy balance in mice. |
| Q37980432 | Hepatitis C virus induced insulin resistance impairs response to anti viral therapy |
| Q26766606 | IL-6 pathway in the liver: From physiopathology to therapy |
| Q38365029 | Immunoregulation by lipids during the development of non-alcoholic steatohepatitis |
| Q40545494 | Increased parenchymal damage and steatohepatitis in Caucasian non-alcoholic fatty liver disease patients with common IL1B and IL6 polymorphisms |
| Q38107461 | Inflammation and liver tumorigenesis |
| Q35402168 | Inflammation-associated interleukin-6/signal transducer and activator of transcription 3 activation ameliorates alcoholic and nonalcoholic fatty liver diseases in interleukin-10-deficient mice |
| Q89693085 | Inflammatory networks cultivate cancer cell metastasis to the liver |
| Q34348905 | Interleukin-6 is an important mediator for mitochondrial DNA repair after alcoholic liver injury in mice |
| Q42051129 | Lack of fibroblast growth factor 21 accelerates metabolic liver injury characterized by steatohepatities in mice |
| Q36288405 | New Approaches for Studying Alcoholic Liver Disease |
| Q83965043 | Oncostatin M produced in Kupffer cells in response to PGE2: possible contributor to hepatic insulin resistance and steatosis |
| Q33817373 | Over-expressing the soluble gp130-Fc does not ameliorate methionine and choline deficient diet-induced non alcoholic steatohepatitis in mice. |
| Q52887942 | Pu-erh tea extract ameliorates high-fat diet-induced nonalcoholic steatohepatitis and insulin resistance by modulating hepatic IL-6/STAT3 signaling in mice. |
| Q38325855 | Retinoids ameliorate insulin resistance in a leptin-dependent manner in mice |
| Q27000742 | STAT proteins - key regulators of anti-viral responses, inflammation, and tumorigenesis in the liver |
| Q38783242 | SULF1/SULF2 reactivation during liver damage and tumour growth |
| Q34940989 | Signal transducer and activator of transcription 3 in liver diseases: a novel therapeutic target |
| Q64376813 | Stanniocalcin 2 Ameliorates Hepatosteatosis Through Activation of STAT3 Signaling |
| Q90540850 | Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 to Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution |
| Q38773189 | The JAK/STAT pathway in obesity and diabetes |
| Q83112894 | The chicken or the egg: adipocytes and hepatic insulin resistance |
| Q99593488 | The palmitoyl acyltransferases ZDHHC5 and ZDHHC8 are uniquely present in DRG axons and control retrograde signaling via the Gp130/JAK/STAT3 pathway |
| Q38983015 | Transforming Growth Factor-β (TGF-β) Directly Activates the JAK1-STAT3 Axis to Induce Hepatic Fibrosis in Coordination with the SMAD Pathway. |
Search more.